BioNTech finds itself in an unusual bind. The Mainz-based biotech is sitting on roughly €16.8 billion in cash and marketable securities, yet its shares are trading near multi-month lows. A new $1 billion buyback launched on May 7 was supposed to send a vote of confidence. Instead, the stock has continued to slide.
The equity closed at €77.05, marking a weekly decline of 6.44%. That leaves the shares more than 27% below their January peak of €105.80 and about 10% under the 200-day moving average. On a monthly basis, the loss comes to 4.88%. The technical picture is one of persistent weakness rather than outright collapse, but the lack of upward momentum is palpable.
Investors are grappling with the stark reality that the COVID-era revenue boom is over. First‑quarter revenue for 2026 dropped to €118.1 million from €182.8 million a year earlier. Management has held firm on its full‑year guidance of €2.0 billion to €2.3 billion, but the market is clearly pricing in a long wait before the oncology pipeline can fill the gap.
That pipeline, however, is what keeps the narrative alive. At the ASCO annual meeting, BioNTech presented encouraging data on Pumitamig, a bispecific T‑cell engager developed with Bristol Myers Squibb. In a study of non‑small‑cell lung cancer, the drug showed promising activity and high response rates when combined with chemotherapy. The pivotal ROSETTA Lung‑02 trial is now being expanded and shifted to a progression‑free survival primary endpoint as it moves into Phase 3. Separately, Gotistobart (partnered with OncoC4) demonstrated durable responses in platinum‑resistant ovarian cancer. In total, BioNTech is running more than 25 Phase 2 and Phase 3 clinical programs, with 13 studies tracking toward registration.
Should investors sell immediately? Or is it worth buying BioNTech?
Just as the company tries to build conviction around this oncology story, a political wildcard has emerged from its home market. On June 3, BioNTech warned that planned healthcare reforms in Germany could influence future investment decisions. The company stopped short of giving specifics, but the message was clear: if Berlin’s regulatory changes make the local environment less attractive, capital will be reallocated elsewhere. For a firm that aims to become a multi‑product company by 2030, planning stability is critical, and the reform debate has injected an extra layer of uncertainty.
On the vaccine front, there was a small positive. In late May, BioNTech and Pfizer received EU approval for an adapted COVID‑19 shot for children aged six months to four years. But with pandemic‑era demand fading, this does little to change the immediate revenue trajectory.
The combination of a declining top line, a long‑gestating cancer pipeline, and now political jitters in Germany leaves the stock in a waiting game. The next major catalyst is likely to come in the second half of the year, when several key data readouts are expected. Closer at hand, second‑quarter earnings are due on August 3, giving investors a chance to assess whether the buyback and the €16.8 billion cash hoard are enough to bridge the gap until those results arrive.
Until then, the shares are caught between two forces. The oncology pipeline offers a powerful long‑term story, but short‑term uncertainties—both commercial and political—are proving a heavy counterweight.
Ad
BioNTech Stock: Buy or Sell?! New BioNTech Analysis from June 5 delivers the answer:
The latest BioNTech figures speak for themselves: Urgent action needed for BioNTech investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from June 5.
BioNTech: Buy or sell? Read more here...
